Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.
Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.
Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.
Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.
Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:
- Obesity treatment applications
- MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Two additional newly FDA-cleared indications
The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Leerink Global Healthcare Conference in March 2025. The company's management team will engage in a fireside chat session during the conference.
The event will be accessible via webcast through the Events section of the Altimmune website, providing investors and interested parties an opportunity to follow the discussion remotely.
Altimmune (NASDAQ: ALT) has announced its Q4 and full year 2024 financial results, highlighting significant progress in its pemvidutide development program. The company reports cash reserves of $131.9 million as of December 31, 2024.
Key developments include:
- Top-line data from Phase 2b IMPACT trial in MASH expected in Q2 2025
- FDA clearance received for two additional pemvidutide indications
- Phase 2 trials for new indications to commence mid-2025
Financial highlights for Q4 2024:
- R&D expenses: $19.8 million
- G&A expenses: $5.1 million
- Net loss: $23.2 million ($0.33 per share)
The company strengthened its Board with two pharmaceutical industry veterans and plans to hold a virtual R&D Day on March 13, 2025.
Altimmune (Nasdaq: ALT) has appointed Teri Lawver and Jerry Durso to its Board of Directors as the company advances into late-stage clinical development for pemvidutide and prepares for transition to a pre-commercial organization.
Lawver brings nearly 30 years of healthcare experience, most recently serving as Chief Commercial Officer at Dexcom where she led the launch of the industry's first over-the-counter glucose biosensor. Previously, she spent 20 years at Johnson & Johnson in senior leadership roles, including global commercial responsibility for Janssen's $16 billion immunology portfolio.
Durso has over 30 years of leadership experience, most recently as CEO of Intercept Pharmaceuticals where he built a successful rare liver disease franchise and led the company through its acquisition by Alfasigma. He previously spent over 20 years at Sanofi in various senior positions.
Both executives will help guide Altimmune's strategic vision to develop and commercialize pemvidutide, which has shown promising effects on liver defatting, weight loss, and serum lipid improvements.
Altimmune (Nasdaq: ALT) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day, during which management will discuss financial results and provide a business update.
The conference call will be accessible through a webcast on Altimmune's Investor Relations website. Interested participants can register online to receive dial-in numbers and a unique PIN for call access. A replay of the call will be available on the company's Investor Relations website for up to three months following the event.
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. EST.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation represents an opportunity for investors and stakeholders to gain insights into the company's developments and strategic direction.
Altimmune (Nasdaq: ALT) announced its addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024. The company's CEO, Vipin K. Garg, highlighted this as an important recognition following a year of major progress. Looking ahead to 2025, the company anticipates significant milestones, including topline data from the Phase 2b IMPACT trial of pemvidutide in MASH expected in Q2. The NBI, established in 1993, tracks Nasdaq-listed biotechnology and pharmaceutical securities that meet specific eligibility criteria including market capitalization, trading volume, and seasoning requirements.
Altimmune (Nasdaq: ALT) announced that their Chief Medical Officer, Dr. Scott Harris, will present at the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. The presentation will focus on body composition data from the Phase 2 MOMENTUM trial of pemvidutide in obesity treatment. Dr. Harris will participate in a panel discussion titled 'Muscle Wasting in Weight Loss Therapy' during the session 'Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues' on Friday, December 6, 2024, at 9:30 am ET.
Altimmune (Nasdaq: ALT) has announced its participation in two upcoming investor conferences. The company's management team will be present at the Annual Evercore HealthCONx Conference in Coral Gables, FL on December 3, 2024, featuring a fireside chat at 10:50 a.m. ET, and the Piper Sandler Annual Healthcare Conference in New York, NY on December 4, 2024, with a fireside chat scheduled for 3:30 p.m. ET. Both sessions will be available via webcast through the Events section of Altimmune's website. The team will also be available for one-on-one meetings during these events.
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®. The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascular health markers. In the trial of 94 subjects, pemvidutide reduced liver fat content by up to 68.5%, total cholesterol by 12.2%, and triglycerides by 44.6% after 12 weeks. The company is currently conducting the Phase 2b IMPACT trial in MASH patients, with results expected in Q2 2025.
